Cell Signaling Technology

Product Pathways - Chromatin Regulation / Epigenetics

SMYD3 (D2Q4V) Rabbit mAb #12859

No. Size Price
12859S 100 µl ( 10 western blots ) ¥3,250.00 现货查询 购买询价 防伪查询
12859 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human,Monkey, Endogenous 42 Rabbit IgG

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting,

Specificity / Sensitivity

SMYD3 (D2Q4V) Rabbit mAb recognizes endogenous levels of total SMYD3 protein. This antibody does not cross-react with other SMYD proteins.

SMYD3 (D2Q4V) Rabbit mAb 兔单抗能够检测内源性SMYD3总蛋白。该抗体不会与其他SMYD蛋白发生交叉反应。

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro357 of human SMYD3 protein.

此单克隆抗体是经由采用合成的与人源 MYD3蛋白的Pro357残基周围序列相对应的肽段免疫动物而生产的。

Western Blotting

Western Blotting

Western blot analysis of extracts from various cell lines using SMYD3 (D2Q4V) Rabbit mAb. Western blot方法检测不同细胞系的提取物,使用的抗体为SMYD3 (D2Q4V) Rabbit mAb。


SET and MYND domain containing protein 3 (SMYD3) is a member of the SET domain-containing family of protein methyltransferases and is localized to both the nucleus and cytoplasm (1-3). Several histone substrates have been identified for SMYD3; however, the data is controversial. In one study, SMYD3 has been shown to methylate histone H3 Lys4 (both di- and tri-methylation) and interact with RNA polymerase II to activate transcription (1). A second study has shown that SMYD3 preferentially methylates histone H4 Lys20 and interacts with nuclear receptor corepressor complex (NCOR) to repress transcription (2). A third study has shown that SMYD3 preferentially methylates histone H4 Lys5 (mono-, di-, and tri-methylation) (3). In addition, SMYD3 has been shown to methylate the endothelial growth factor receptor 1 (VEGFR1) on Lys831 and stimulate its kinase activity (4). Regardless of the preferred protein substrates, it is clear that SMYD3 functions as an oncogene. Research studies have shown SMYD3 is highly over-expressed in liver, breast, and rectal carcinomas. Over-expression of SMYD3 in multiple cell lines enhances proliferation, adhesion, and migration, while reduced expression results in significant suppression of cell growth (1,5-10). In addition, multiple cancer cell lines express both full length SMYD3 and a cleaved form of SMYD3 lacking the N-terminal 34 amino acids, and the cleaved form shows increased methyltransferase activity toward histone H3 (11).

SET and MYND domain containing protein 3 (SMYD3)是含SET结构域的蛋白甲基转移酶家族的成员,定位于核和胞质内(1-3)。已经确认了几种SMYD3的底物;但是数据仍存在争议。在一个研究中,SMYD3 能够甲基化组蛋白 H3的Lys4位点(二,三甲基化都有),并且能够与RNA聚合酶相互作用激活转录(1)。 第二个研究表明,SMYD3优先甲基化组蛋白H4 Lys20位点,能够与nuclear receptor corepressor complex (NCOR)相互作用从而阻遏转录(2)。 第三个研究显示,SMYD3优先甲基化组蛋白H4 Lys5位点(单,二,三甲基化)(3)。此外,SMYD3还能够甲基化endothelial growth factor receptor 1 (VEGFR1)的Lys831位点,并激活其激酶活性(4)。不论蛋白底物的优先性如何,有一点非常清楚就是,SMYD3的功能是癌基因。研究已经表明SMYD3 在肝癌,乳腺癌以及直肠癌中高度过表达。在多种细胞系中过表达的SMYD3会增强其增殖,粘附以及迁移,而降低表达水平会产生明显的细胞生长抑制(1,5-10)。此外,在多种癌细胞系表达全长SMYD3和缺失N-末端 34个氨基酸的截短型SMYD3,结果显示截短型对组蛋白H3的甲基转移酶活性升高(11)。

  1. Hamamoto, R. et al. (2004) Nat Cell Biol 6, 731-40.
  2. Foreman, K.W. et al. (2011) PLoS One 6, e22290.
  3. Van Aller, G.S. et al. (2012) Epigenetics 7, 340-3.
  4. Kunizaki, M. et al. (2007) Cancer Res 67, 10759-65.
  5. Luo, X.G. et al. (2007) J Biosci Bioeng 103, 444-50.
  6. Wang, S.Z. et al. (2008) BMB Rep 41, 294-9.
  7. Zou, J.N. et al. (2009) Cancer Lett 280, 78-85.
  8. Luo, X.G. et al. (2009) IUBMB Life 61, 679-84.
  9. Luo, X.G. et al. (2010) IUBMB Life 62, 194-9.
  10. Ren, T.N. et al. (2011) Med Oncol 28 Suppl 1, S91-8.
  11. Silva, F.P. et al. (2008) Oncogene 27, 2686-92.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :